
Locally Confined Prostate Cancer (Stage B2–C): Used in combination with flutamide and radiotherapy. Initiated 8 weeks prior to radiation and continued during therapy.
Advanced Prostate Cancer: Palliative treatment for metastatic diseas.
Chemical Structure: Synthetic decapeptide GnRH analog ([D-Ser(Bu⁶),Azgly¹⁰]).
Matrix: Biodegradable D,L-lactic and glycolic acids copolymer (36.0 mg total implant weight).
Release Profile: Sustained release over 12 weeks.
1. Dose: 10.8 mg administered subcutaneously every 12 weeks.
2. Site: Anterior abdominal wall below the navel line.
3. Technique:
3.1 Aseptic technique; avoid muscle/peritoneum penetration.
3.2 Insert needle at 30–45° angle; no aspiration required.
3.3 Monitor for vascular injury (risk in low BMI or anticoagulated patients).
4. Missed Dose: Adhere to 12-week schedule; brief delays permissible.
Goserelin (Zoladex) has brought good news to patients who need to treat diseases such as prostate cancer,...
Goserelin sustained-release injection is suitable for prostate cancer, uterine leiomyoma, and breast cancer....
Goserelin is a hormone modulator commonly used to treat hormone-dependent diseases such as breast cancer,...
As a hormone regulator, Goserelin mainly inhibits the secretion of gonadotropin-releasing hormone (GnRH). By...
Goserelin is a hormone regulator, commonly used to treat a variety of hormone-dependent diseases, including...
Goserelin is a synthetic analog of luteinizing hormone-releasing hormone (LHRH), mainly used to treat...